Semaglutide helps with weight loss and improves overall body weight management
#ObesityMedicine #MetabolicHealth #GLP1 #ClinicalTrials #HealthcareInnovation #Semaglutide #Orforglipron #CagriSema #Retatrutide #Wegovy To view or add a comment, sign in : Eli Lilly and Company just released Phase 3 ATTAIN-MAINTAIN data on orforglipron, a once daily oral GLP-1 receptor agonist, and I think it speaks directly to one of the most painful realities my patients face: not losing weight, but it - Participants first completed 72 weeks on high-dose injectable semaglutide (Wegovy) or tirzepatide (Zepbound) in SURMOUNT-5, with very large average weight reductions
It must also be assessed whether medication-based weight management is generally appropriate and which treatment approach may suit the patients medical circumstances
These are not outlier results, as nearly a third of patients in a well-controlled clinical trial hit that threshold
Taste buds: cells, signals and synapses
BPC-157 (stable version) 300 mcg